Ironwood Pharmaceuticals Net Worth
Ironwood Pharmaceuticals Net Worth Breakdown | IRWD |
Ironwood Pharmaceuticals Net Worth Analysis
Ironwood Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Ironwood Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Ironwood Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Ironwood Pharmaceuticals' net worth analysis. One common approach is to calculate Ironwood Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Ironwood Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Ironwood Pharmaceuticals' net worth. This approach calculates the present value of Ironwood Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Ironwood Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Ironwood Pharmaceuticals' net worth. This involves comparing Ironwood Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Ironwood Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Ironwood Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ironwood Pharmaceuticals' net worth research are outlined below:
| Ironwood Pharmaceuticals generated a negative expected return over the last 90 days | |
| Ironwood Pharmaceuticals has high historical volatility and very poor performance | |
| Ironwood Pharmaceuticals may become a speculative penny stock | |
| Ironwood Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 351.41 M. Net Loss for the year was (1 B) with profit before overhead, payroll, taxes, and interest of 241.46 M. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Sarissa Capital Management LP Reduces Stake in Innoviva Inc. |
Ironwood Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ironwood Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ironwood Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Ironwood Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ironwood Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ironwood Pharmaceuticals backward and forwards among themselves. Ironwood Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Ironwood Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 3.6 M | Geode Capital Management, Llc | 2024-12-31 | 3.3 M | Millennium Management Llc | 2024-12-31 | 2.2 M | Ubs Group Ag | 2024-12-31 | 2.2 M | Charles Schwab Investment Management Inc | 2024-12-31 | 2 M | Northern Trust Corp | 2024-12-31 | 1.6 M | Deutsche Bank Ag | 2024-12-31 | 1.6 M | Two Sigma Advisers, Llc | 2024-12-31 | 1.2 M | Jupiter Asset Management Limited | 2024-12-31 | 1.2 M | Blackrock Inc | 2024-12-31 | 23 M | Vanguard Group Inc | 2024-12-31 | 19.5 M |
Follow Ironwood Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 225.64 M.Market Cap |
|
Project Ironwood Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.47) | (2.34) | |
| Return On Capital Employed | (5.58) | (5.30) | |
| Return On Assets | (2.45) | (2.32) | |
| Return On Equity | 2.60 | 2.73 |
When accessing Ironwood Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Ironwood Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Ironwood Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Ironwood Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ironwood Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ironwood Pharmaceuticals' management manipulating its earnings.
Evaluate Ironwood Pharmaceuticals' management efficiency
Ironwood Pharmaceuticals has return on total asset (ROA) of 0.1481 % which means that it generated a profit of $0.1481 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.7472) %, meaning that it created substantial loss on money invested by shareholders. Ironwood Pharmaceuticals' management efficiency ratios could be used to measure how well Ironwood Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 2.73, whereas Return On Tangible Assets are projected to grow to (2.34). At present, Ironwood Pharmaceuticals' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 807.8 M, whereas Non Current Assets Total are forecasted to decline to about 143 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.01) | (2.11) | |
| Tangible Book Value Per Share | (2.03) | (2.13) | |
| Enterprise Value Over EBITDA | (2.34) | (2.45) | |
| Price Book Value Ratio | (4.62) | (4.39) | |
| Price Fair Value | (4.62) | (4.39) | |
| Enterprise Value Multiple | (2.34) | (2.45) | |
| Enterprise Value | 2.2 B | 2.4 B |
Effective management at Ironwood Pharmaceuticals has been a driving force behind its market achievements. We assess the correlation between management practices and financial success to determine the stock's value.
Enterprise Value Revenue 2.0937 | Revenue | Quarterly Revenue Growth (0.23) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ironwood Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ironwood Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ironwood Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ironwood Pharmaceuticals time-series forecasting models is one of many Ironwood Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ironwood Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Ironwood Pharmaceuticals Earnings per Share Projection vs Actual
Ironwood Pharmaceuticals Corporate Management
| Thomas McCourt | Chief Commercial Officer and Sr. VP of Marketing and Sales | Profile | |
| Jana Noeldeke | Basel Leader | Profile | |
| Elizabeth Geary | Team Talent | Profile | |
| Tammi Gaskins | Senior Officer | Profile | |
| Ronald Silver | Corporate Officer | Profile | |
| Marcel Moulaison | Vice Operations | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share 0.01 | Revenue Per Share | Quarterly Revenue Growth (0.23) | Return On Assets |
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.